Literature DB >> 16489655

Serum soluble interleukin-2 receptor levels in patients with chronic hepatitis B virus infection and its relation with anti-HBc.

Ping Xiao1, Qing-Feng Chen, Yan-Ling Yang, Zhen-Hua Guo, Hong Chen.   

Abstract

AIM: To investigate the relationship between serum soluble interleukin-2 receptor (sIL-2R) level and anti-HBc in patients with chronic hepatitis B virus (HBV) infection.
METHODS: Sera from 100 patients with chronic HBV infection and 30 healthy controls were included in this study. The patients were divided into group A [HBsAg (+), HBeAg (+) and anti-HBc (+), n=50] and group B [HBsAg (+), HBeAg (+) and anti-HBc (-), n=50]. sIL-2R levels were determined using ELISA. HBV DNA and alanine aminotransferase (ALT) were also detected.
RESULTS: Serum sIL-2R levels were significantly higher in patients with chronic HBV infection than in healthy controls. Moreover, serum sIL-2R levels were significantly higher in patients with HBsAg (+), HBeAg (+) and anti-HBc (+) (976.56+/-213.51x10(3) U/L) than in patients with HBsAg (+), HBeAg (+) and anti-HBc (-) (393.41+/-189.54x10(3) U/L, P<0.01). A significant relationship was found between serum sIL-2R and ALT levels (P<0.01) in patients with chronic HBV infection, but there was no correlation between sIL-2R and HBV DNA levels. The anti-HBc status was significantly related to the age of patients (P<0.01).
CONCLUSION: The high sIL-2R level is related to positive anti-HBc in chronic hepatitis B patients. Positive anti-HBc may be related to T-lymphocyte activation and negative anti-HBc may imply immune tolerance in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489655      PMCID: PMC4066074          DOI: 10.3748/wjg.v12.i3.482

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children.

Authors:  C L Lai; H J Lin; J N Lau; A S Flok; P C Wu; H T Chung; L K Wong; M P Leung; C Y Yeung
Journal:  Q J Med       Date:  1991-02

2.  Alpha-interferon treatment in Chinese patients with chronic hepatitis B.

Authors:  A S Lok; C L Lai; P C Wu; J Y Lau; E K Leung; L S Wong; Y L Fung
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

3.  Effects of alpha-interferon and prednisone on serum-soluble interleukin-2 receptor (sIL-2R) in chronic hepatitis B infection.

Authors:  N W Leung; J C Leung; J S Tam; J T Lau; K N Lai
Journal:  Am J Gastroenterol       Date:  1992-01       Impact factor: 10.864

4.  The molecular basis for the generation of the human soluble interleukin 2 receptor.

Authors:  L A Rubin; F Galli; W C Greene; D L Nelson; G Jay
Journal:  Cytokine       Date:  1990-09       Impact factor: 3.861

Review 5.  Hepatitis B virus. The major etiology of hepatocellular carcinoma.

Authors:  R P Beasley
Journal:  Cancer       Date:  1988-05-15       Impact factor: 6.860

6.  Interleukin-2 activity and serum levels of soluble interleukin-2 receptors in chronic active hepatitis B.

Authors:  F Casafont; S Echevarria; F Pons Romera
Journal:  Dig Dis Sci       Date:  1990-08       Impact factor: 3.199

Review 7.  The soluble interleukin-2 receptor: biology, function, and clinical application.

Authors:  L A Rubin; D L Nelson
Journal:  Ann Intern Med       Date:  1990-10-15       Impact factor: 25.391

8.  Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease.

Authors:  C Müller; P Knoflach; C C Zielinski
Journal:  Hepatology       Date:  1989-12       Impact factor: 17.425

9.  Serum levels of soluble interleukin-2 receptors in acute and chronic viral hepatitis.

Authors:  A Alberti; L Chemello; G Fattovich; P Pontisso; G Semenzato; C Colletta; F Vinante; G Pizzolo
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

10.  T lymphocyte activation in chronic hepatitis B infection: interleukin 2 release and its receptor expression.

Authors:  K N Lai; J C Leung; J S Tam; N W Leung
Journal:  Am J Gastroenterol       Date:  1989-12       Impact factor: 10.864

View more
  6 in total

1.  Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides.

Authors:  Niko Escher; Martin Kaatz; Christian Melle; Christina Hipler; Mirjana Ziemer; Dominik Driesch; Uwe Wollina; Ferdinand von Eggeling
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

Review 2.  Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections.

Authors:  Xuefen Li; Xia Liu; Li Tian; Yu Chen
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

3.  Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Guosheng Yuan; Yuchen Zhou; Hao Zhang; Junjie Wang; Nianhuan Yang; Yabing Guo; Dinghua Yang; Yuanping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study.

Authors:  Wei Jia; Liu-Wei Song; Yu-Qing Fang; Xiao-Feng Wu; Dan-Yang Liu; Chun Xu; Xiao-Mei Wang; Wen Wang; Dong-Xia Lv; Jun Li; Yong-Qiong Deng; Yan Wang; Na Huo; Min Yu; Hong-Li Xi; Dan Liu; Yi-Xing Zhou; Gui-Qiang Wang; Ning-Shao Xia; Ming-Xiang Zhang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

5.  Cytokine profile during occult hepatitis B virus infection in chronic hepatitis C patients.

Authors:  Camilla Rodrigues de Almeida Ribeiro; Nathalia Alves Araújo de Almeida; Katrini Guidolini Martinelli; Marcia Amendola Pires; Carlos Eduardo Brandao Mello; José J Barros; Vanessa Salete de Paula
Journal:  Virol J       Date:  2021-01-12       Impact factor: 4.099

6.  Characterization of the Physiological Response following In Vivo Administration of Astragalus membranaceus.

Authors:  Karen Denzler; Jessica Moore; Heather Harrington; Kira Morrill; Trung Huynh; Bertram Jacobs; Robert Waters; Jeffrey Langland
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-12       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.